BioSpace News Archive

Gelesis, the maker of Plenity for weight management, reported financial results for the first quarter of 2022.

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced financial results for the three-month period ended March 31, 2022 and provided a corporate update.

Equillium, Inc. announced financial results for the first quarter 2022 and provided an update on its corporate development and clinical programs.

Viveve Medical, Inc. reported financial results for the quarter ended March 31, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET.

Agios Pharmaceuticals, Inc. announced that clinical and translational data will be presented at the European Hematology Association Annual Congress, hosted virtually and in person in Vienna on June 9-12, 2022.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced a poster presentation at the European Hematology Association Congress being held June 9-12, 2022.

Rockley Photonics Holdings Limited, a global leader in photonics-based health monitoring and communications solutions, announced its financial results for the first quarter ended March 31, 2022.

Astellas Pharma Inc. will share new research during the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7 and the European Hematology Association 2022 Hybrid Congress from June 9-12.

Wugen, Inc. announced it will present new preclinical data highlighting the anti-tumor activity of Wugen’s lead memory natural killer product candidate WU-NK-101 at the European Hematology Association 2022 Hybrid Congress being held June 9-12, 2022, virtually and in-person in Vienna, Austria.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that an abstract providing safety and efficacy data from the ongoing CTX130™ clinical trial for patients with T-cell lymphoma has been accepted for oral presentation at the Annual European Hematology Association (EHA) 2022 Hybrid Congress.